Cardiac Biomarkers Market Size was valued at USD 4.78 Billion in 2023. The cardiac biomarkers market industry is projected to grow from USD 5.44 Billion in 2024 to USD 13.55 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.07% during the forecast period (2024 - 2032). Major market drivers anticipated to drive the market in the upcoming years include an increase in the senior population and an increase in the number of patients experiencing heart attacks and chest pain as a result of changes in lifestyle.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Due to technological developments in cardiac biomarkers, rising requests for point-of-care (POC) cardiac testing kits, elevated incidence of acute coronary syndrome, and elevated specificity in the identification of cardiac diseases, particularly myocardial infarction, cardiac biomarkers are on the rise. Various combination procedures that identify the presence of biomarkers are also included in cardiac test kits, making it easier to diagnose heart problems. These endogenous chemicals, such as hormones, enzymes, and proteins, are released into the blood during cardiovascular situations and serve as biomarkers for abnormalities in the heart's function. To identify and diagnose serious cardiac disorders like heart attacks, myocardial infarction, acute coronary syndrome, and other critical cardiac conditions, healthcare practitioners are now concentrating on recognizing these specific markers.
Market participants have created a variety of tests to detect the presence of these biomarkers precisely and quickly, which have proved crucial in the early detection of cardiovascular problems. These kits are in higher demand since they enable speedy diagnosis and prompt results, which cut down on the time needed for diagnosis and speed up the healing process. Additionally, they aid in identifying risk factors before bad cardiac events happen and diagnose chest pain. Cardiovascular illnesses constitute the main cause of mortality or morbidity in the United States. Since they help understand cardiovascular disorders' pathophysiology better, businesses are currently concentrating on identifying cardiac biomarkers. The decrease in heart attack mortality is anticipated to hurt the adoption of products. The market is expected to grow due to ongoing studies on cardiovascular therapies and the introduction of quick and new biomarker testing. Major market players are investing in the study and development of novel biomarkers for evaluating, prognosis, and forecasting cardiovascular disorders.
The cardiac biomarker NTProBNP, developed by Pathkind Labs and Roche Diagnostics, is about to be made available for use in the treatment of Type 2 Diabetes (T2DM) and the detection of heart failure in patients. This declaration is made considering the urgent need for action caused by the rising incidence of heart failure amongst T2D patients in India. One hundred seven million adults worldwide have been diagnosed with T2DM. According to the Trivandrum Heart-Failure Registry, T2DM was found in 55% of these hospitalized patients, making it a common comorbidity. Additionally, these studies predicted an expected 18% increase in the annual incidence of coronary artery disease in India.
ly, the burden of cardiovascular diseases (CVDs) is increasing as a result of a number of causes, including smoking, diabetes, obesity, and alterations in lifestyle. The National Centre for Health Statistics estimates that 1 in 4 deaths in the United States occur as a result of coronary artery disease (CAD). The Centers for Disease Control and Prevention estimate that there are roughly 1.5 million myocardial infarction cases reported each year in the US. Additionally, 103,000 people in the UK get myocardial infarction annually, according to Patient Platform Limited. During the projection period, it is expected that one of the key factors influencing market CAGR will be the rising prevalence of cardiovascular illnesses. Additionally, the coronavirus disease of 2019 (COVID-19) has been reported in more than 129 countries worldwide, according to the present situation for the year 2020. The impact of COVID-19 on patients with cardiovascular disease is significant, and those who contract the virus are likely to develop heart failure, acute coronary syndrome, and other cardiovascular diseases. Although COVID-19 impacts the respiratory system and other related organs, it has a significant impact on cardiovascular problems, according to an article released by NCBI in March 2020. Furthermore, 16.4% of 1,527 patients with COVID-19 in various studies from China reported co-morbid disorders. 9.7%, 16.4%, and 17.1% of the patients out of this group, respectively, reported having diabetes, cardiovascular disease, and hypertension. These are a few of the elements that are projected to encourage the use of biomarker testing ly, fueling market expansion.
It is predicted that the market would increase due to vigorous research and development on cardiovascular therapies and the advent of quick and new biomarker testing. For the diagnosis, prognosis, and predictive analysis of cardiovascular illnesses, major market participants are investing in the research and development of new biomarkers. Siemens' high-sensitivity troponin I tests (TnIH) to help with the early identification of myocardial infarctions were approved by the U.S. Food and Drug Administration (FDA) in July 2019. During the projection period, it is predicted that the development of such innovative tests for the identification of these biomarkers would increase demand for these tests and, as a result, drive the market's growth rate.
The demand for quick and POC cardiac biomarkers testing is predicted to rise in part due to the rising prevalence of cardiovascular diseases. Rapid biomarker test kits are being developed by major market players, which is anticipated to fuel market expansion. Comparing the point-of-care test to customary laboratory-based diagnostics, the former offers clinical advantages such as faster diagnosis. For instance, F. Hoffmann-La Roche AG gained FDA approval in March 2017 to use the Elecsys Troponin T (TnT) Gen 5 Stat blood test to diagnose myocardial infarction. When compared to Roche's traditional TnT test, the test's 9-minute turnaround time reduces the time needed to diagnose cases by almost 3 hours. Rapid POC tests are increasingly being used in emerging and developed nations to find these kinds of biomarkers. Thus, driving the cardiac biomarkers market revenue.
The cardiac biomarkers market segmentation, based on type includes Creatine Kinase (CK-MB), Troponins T and Imyoglobin, BNPs, IMA and Others. The troponins T and imyoglobin segment dominated the market. The troponins T and imyoglobin test is used, among other things, to diagnose myocardial infarction and acute coronary syndrome. One of the key factors predicted to drive the demand for the troponins T and imyoglobin test during the forecast period is the increased prevalence of myocardial infarction and acute coronary syndrome.
The cardiac biomarkers market segmentation, based on location of testing, includes Point of Care and Laboratory Testing. The laboratory testing category generated the most income. This can be due to the benefits that laboratory testing provides, including its high sensitivity, specificity, scalability, and cost-effectiveness. Additionally, these labs make it easier to test any kind of sample. Clinical decision-making requires the use of diagnostic laboratory services.
Figure 1 Cardiac Biomarkers Market, by Location of Testing, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The cardiac biomarkers market segmentation, based on application, includes Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome and Atherosclerosis. The acute coronary syndrome category generated the most income as compared to high-income countries, the burden of sickness is fast increasing in low- and middle-income countries. The prevalence of the condition is being fueled by elements including quick urbanization and an increase in sedentary jobs. The main diagnostic techniques used to identify the condition now include cardiac troponin T and I biomarker assays.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cardiac biomarkers market area will dominate this market. This can be ascribed to the advanced healthcare system and the widespread use of cardiac biomarkers as a diagnostic and prognostic tool for diseases. The need for testing products is being driven by the growing elderly population's need for biomarker testing to diagnose diseases such acute myocardial infarction.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 CARDIAC BIOMARKERS MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe cardiac biomarkers market accounts for the second-largest market share because there are renowned research institutions and market players there. Additionally, the expansion of the industry can be attributed to an increase in the number of partnerships between regional universities and biomarker suppliers, government and industry R&D initiatives involving biomarkers, and the significant initiatives being made to raise awareness of the advantages of biomarkers. Further, the German cardiac biomarkers market held the largest market share, and the UK cardiac biomarkers market was the fastest growing market in the European region
The Asia-Pacific Cardiac biomarkers Market is expected to grow at the fastest CAGR from 2024 to 2032 due to improved affordability for sophisticated cardiac diagnostics, national modernization, and greater disposable income. Government funding for target disease and other research, as well as healthcare costs, have increased due to the rising incidence of cardiovascular diseases (CVDs) in this area. Moreover, China’s cardiac biomarkers market held the largest market share, and the Indian cardiac biomarkers market was the fastest growing market in the Asia-Pacific region.
Cardiac Biomarkers Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the cardiac biomarkers market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, cardiac biomarkers industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the cardiac biomarkers industry to benefit clients and increase the market sector. In recent years, the cardiac biomarkers industry has offered some of the most significant advantages to market. Major players in the cardiac biomarkers market attempting to increase market demand by investing in research and development operations include Novartis AG (Switzerland), Quidel Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany) and Thermo Fisher Scientific Inc (US).
Siemens AG is a technological firm. Its operations span the disciplines of electrification, automation, and digitalization. The firm creates, develops, and manufactures items, as well as installs complicated systems and projects. It also offers a wide range of customized solutions for specific needs. Siemens is primarily concerned with power generation and distribution, as well as sophisticated infrastructure for buildings and distributed energy systems. In April 2021, the Atellica VTLi patient-side immunoassay analyzer from Siemens Healthineers provides high-sensitivity cardiac troponin I (hs-cTnI) testing findings in eight minutes using a fingerstick blood sample.
Quidel Corp develops, manufactures, and markets quick diagnostic testing systems for the detection and diagnosis of critical diseases and other medical disorders. Immunoassays, molecular assays, virology products such as traditional cell lines, media, specimen collecting equipment, and controls; and speciality goods such as metabolic bone indicators and enzyme linked immunosorbent assays (ELISA) and reagents are among its primary products. Physician offices, hospitals, universities, retail clinics, clinical and reference laboratories, urgent care clinics, pharmacies, and wellness screening facilities are all served by the company's goods.
Key Companies in the cardiac biomarkers market include
Cardiac Biomarkers Industry Developments
September 2022 "Heart Assure," a specific test that can gauge a person's risk of experiencing a cardiac episode, was introduced by SRL Diagnostics. A quick blood test called high-sensitivity troponin I can accurately forecast a cardiac damage by giving a heart health risk score.
June 2022 The Zeno SWATH DIA represents a significant advancement in biomarker discovery and translation workflows and was introduced by SCIEX, a company of Danaher Corporation and a world leader in life science analytical technology. According to a recent study, cardiac biomarkers in heart failure assessments may help identify patients whom older diseases would otherwise miss. In the ARIC trial, researchers discovered that adding cardiac biomarkers to HF assessments may help identify patients whom more traditional illness classifications would have otherwise missed. The inclusion of elevated cardiac troponin or natriuretic peptide reclassified one in five asymptomatic elderly participants from Stage A to Stage B in the research.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 4.78 Billion |
| Market Size 2024 | USD 5.44 Billion |
| Market Size 2032 | USD 13.55 Billion |
| Compound Annual Growth Rate (CAGR) | 12.07% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Location of Testing, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novartis AG (Switzerland), Quidel Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany) and Thermo Fisher Scientific Inc (US) |
| Key Market Opportunities | Increase in demand for disease-specific treatment & research |
| Key Market Dynamics | Increasing prevalence of cardiovascular and lifestyle-related diseases |
Cardiac Biomarkers Market Highlights:
Frequently Asked Questions (FAQ) :
The cardiac biomarkers market size was valued at USD 4.78 Billion in 2023.
The market is projected to grow at a CAGR of 12.07% during the forecast period, 2024-2032.
North America had the largest share in the market.
The key players in the market are Novartis AG (Switzerland), Quidel Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany) and Thermo Fisher Scientific Inc (US).
The acute coronary syndrome category dominated the market in 2023.
The laboratory testing category had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
